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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A148Methods: PEG-polyamino acid block copolymer was used as a carrier of
mRNA. We injected 10 ml solution of polyplex nanomicelles carrying
various amount of mRNA of luciferase or green ﬂuorescent protein
(GFP) into mouse knee joints. The luciferase mRNA expression was
visualized at different time points by the IVIS imaging system. GFP
expression was analyzed in histological sections. For mRNA intro-
duction into OA cartilages, OAwas induced by surgically transecting the
medial collateral ligament and removing the medial meniscus in knee
joints of 8-week old male C57BL/6 mice. A month after the surgery, the
development of OAwas conﬁrmed by safranin-O staining and the OARSI
scoring system. We then injected 10 ml solution of polyplex nano-
micelles carrying mRNA of interest into OA knee joints every other day
or once every 4 days for 2 weeks.
Results: In vivo imaging of luciferase activities revealed that intra-
articular injections of polyplex nanomicelles carrying luciferase mRNA
induced the production of functional luciferase proteins around the
knee joints in mice. Luciferase activities were observed at 24 hours after
injection and they were maintained for more than 4 days. When we
injected polyplex nanomicelles carrying GFP into intact and surgically-
induced OA knee joints in mice, GFP expression was observed not only
in both intact and OA cartilages, but also in the meniscus. There was no
symptom associated with immune reactions in the mRNA injected
joints.
Conclusions: These results indicate that the polyplex nanomicelle
successfully introduced exogenous mRNA into cells around joints,
supporting the therapeutic potential of this strategy in the treatment of
OA. mRNA introductionwill enable us to utilize transcription factors for
the treatment of degenerative diseases in disease stage-speciﬁc man-
ners. Thus, this is an important initial step of the development of mRNA
introduction-based therapeutic strategies for OA.
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HUMAN CARTILAGE REPAIR USING HUMAN MESENCHYMAL STEM
CELLS AND COLLAGEN SCAFFOLDS
C. Sanjurjo Rodríguez y, T. Hermida Gomez z, I. Fuentes Boquete y,
F. De Toro Santos y, F. Blanco García z, S. Díaz Prado, Sr. y. yUniversidade
da Coru~na, A Coru~na, Spain; z Instituto de Investigacion Biomedica de A
Coru~na, A Coru~na, Spain
Purpose: The purpose was to study chondrogenesis of adult human
Bone Marrow Mesenchymal Stem Cells (hBMSCs) when culture on
collagen (Col) biomaterials. Furthermore, we evaluated the usefulness
of the generated chondrogenic constructs to repair cartilage in an in
vitro lesion model.
Methods: hBMSCs were cultured during 30 days in chondrogenic
medium, with Transforming growth factor b-3 (TGFb-3), and in a con-
trol of DMEM medium on type I Col biomaterials. We have tested
growth and cell morphology on the constructs by histochemical and
Scanning (SEM) and Transmission (TEM) Electron Microscopy. Chon-
drogenic differentiation was evaluated in all the constructs by histo-
chemical and immunohistochemistry analyses and molecular biology. 3
mm lesions were made in human cartilage biopsies and were pre-
treated with 10ng/ml IL-b for 24 hours. 2x105 BMSCs were seeded on
type I Col biomaterials, introduced inside the lesion, and cultured
during 30 days in chondrogenic medium with TGFb-3. Repaired tissue
was evaluated by histochemistry and immunohistochemistry, and
macroscopically using the ICRS scale.
Results: Histology showed that hBMSCs have grown through the scaf-
folds, being the cell percentage higher than 75% in the chondrogenic
constructs. It was observed a big amount of extracellular matrix (ECM),
which showed proteoglycan and type II Col positivity in chondrogenic
but not in control constructs. By measurement of relative expression
levels (REL), type II Col and aggrecan gene expression was seen only in
cells grown in chondrogenic medium. Electron microscopy showed a
big amount of mitochondria and oval/rounded shape cells in chondro-
genic samples. In the in vitro model, histochemistry showed that after
30 days, the cells ﬁlled almost the 90% of the lesion with a cellular
density in the graft higher than the native cartilage (Fig. 1A, H-E). We
found integration of the neotissue with the border of the lesion.
Regarding the ECM of the neotissue was a mixture of hyaline- and ﬁbro-
cartilage, ﬁnding chondrocytes inside lacunas and an ECM positive for
type II Col and aggrecan (Figure 1A, COL II and AGG). In the macroscopic
ICRS assessment, the score of the repair was 21 out of 24 points (Fig. 1B).
Conclusions: Data showed that hBMSCs are able to grow on Col bio-
materials and differentiate to a chondrocityc-like phenotype. Thesechondrogenic constructs are able to repair an in vitro human cartilage
lesion after a 24-hour-pretreatment with 10ng/ml IL-b. Acknowledge-
ments: Opocrin S.P.A.; CAM (S2009/MAT-1472); CIBER-BBN; Red Gallega
de Terapia Celular, Xunta de Galicia (R2014/050); GPC, Xunta de Galicia
(GPC2014/048); Fundacion Espa~nola de Reumatología (2014 grant);
Fundacion Profesor Novoa Santos.Cell Signaling
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VIPERIN; A NOVEL CHONDROGENIC REGULATOR
M.M. Steinbusch y, M.M. Caron y, F. Eckmann z, E. Lausch z,
L.W. van Rhijn y, B. Zabel z, T.J. Welting y. yDept. of Orthopaedic Surgery,
Lab. for Experimental Orthopaedics, Maastricht Univ. Med. Ctr.,
Maastricht, Netherlands; zCtr. for Paediatrics and Adolescent Med., Univ.
of Freiburg, Freiburg, Germany
Purpose: The ribonuclease mitochondrial RNA processing (RMRP) gene
encodes the RNA component of a multi-protein-RNA complex called
RNase MRP. Mutations in the RMRP gene cause Cartilage Hair Hypo-
plasia (CHH). The main phenotypic hallmark of CHH is dwarﬁsm, pre-
sumably caused by impaired growth plate development. Our
preliminary data indeed show that RMRP is involved in chondrogenic
differentiation; however, it is unclear via which mechanism. Viperin is
an antiviral protein, located in the endoplasmic reticulum (ER; location
of protein synthesis and secretion), and its mRNA is a known substrate
of RNase MRP cleavage activity. As such, viperin expression has shown
to be increased in CHH patient cells and during knockdown (KD, RNAi)
of RNaseMRP subunits, including RMRP RNA itself. As the chondrogenic
function of RMRP is unclear and it is not known howmutations in RMRP
cause CHH, we hypothesize that viperin functions as a chondrogenic
regulator downstream of RNase MRP.
Methods: To investigate the expression of viperin during chon-
drogenic differentiation in vivo, viperin was detected in day 1
mouse growth plates by immunohistochemistry. Expression of
viperin mRNA and protein was determined by RT-qPCR / Western
blot in chondrogenically differentiating ATDC5 cells in the pres-
ence or absence of 1 nM bone morphogenic protein (BMP)-2 or -7.
KD of viperin expression was achieved via RNAi and protein
secretion was measured upon transfection of a secretable CMV-
Gaussia Luciferase.
Results: To investigate whether viperin plays a role in developing
chondrocytes in vivo, day 1 mouse growth plates were stained for
viperin. Profound viperin staining was detected in hypertrophic
chondrocytes. However, viperin was also expressed in a sub-
population of proliferative chondrocytes. In these cells a perinuclear
staining could be observed, which is in agreement with the local-
ization of viperin in the ER. To determine the role of viperin
expression in more detail, viperin gene expression dynamics were
determined during chondrogenic differentiation of ATDC5 cells.
Expression of viperin mRNA and protein was ﬁrst detected at day 4 in
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(day 5), after which viperin levels gradually decreased until day 14
(comparable to day 4 expression). To investigate with which chon-
drocyte phenotype viperin expression is primarily associated (chon-
drogenic or hypertrophic), its expression was assessed in the
presence or absence of hypertrophic inducer BMP-2 or hypertrophic
suppressor BMP-7. Viperin gene expression was greatly induced by
exposure of ATDC5 cells to BMP-2, while BMP-7 suppressed viperin
expression, indicating a positive association between viperin and the
level of chondrocyte hypertrophy. Viperin functionality during ATDC5
chondrogenic differentiation was investigated by interfering with
viperin expression using RNAi. Viperin expression was targeted from
day 3 in differentiation onward and the cells were analyzed at day 7.
KD of viperin resulted in 90% reduced expression of Col2a1 mRNA at
day 7 in differentiation. Interestingly, gene expression of the hyper-
trophic markers Mef2c and Col10a1 was not inﬂuenced (Figure 1A).
As the viperin protein is located in the ER, the main location for
protein secretion, and chondrogenic differentiation requires vast
amounts of extracellular matrix synthesis and protein secretion, we
explored a possible link between viperin and protein secretion. KD of
viperin resulted in reduced protein secretion and an increased gene
expression of Chop, a commonly used marker for ER stress (Figure 1
A/B).
Conclusions: Overall, our data show that viperin is expressed in
several stages of chondrocyte development and that its expression
may be regulated via hypertrophic extracellular cues. KD of viperin
speciﬁcally induced Chop levels and abrogated the expression of
Col2a1 mRNA, while leaving Col10a1 mRNA expression unaffected.
This suggests that viperin KD induces ER stress and skews the
chondrocyte phenotype towards hypertrophy. Moreover, the link
between viperin and protein secretion in chondrocytes suggest that
mutations in the RMRP gene may lead to the CHH-associated
dwarﬁsm via abnormal protein-secretory processes. In our ongoing
research we are deﬁning the link between viperin, ER stress and
chondrocyte hypertrophy, and investigating the role of viperin in
chondrocyte protein secretion / extracellular matrix synthesis. Our
data are the ﬁrst to implicate the antiviral protein viperin as a
chondrogenic regulator.
Figure 1. A) KD of viperin expression by RNAi results in a 90% reduction
of Col2a1 gene expression at day 7 in ATDC5 chondrogenic differ-
entiation. Expression of the hypertrophic markers Col10a1 and Mef2c
was not affected; skewing cells towards hypertrophy. KD of viperin also
results in increased ER stress indicated by increased expression of
Chop. B) Moreover, viperin KD resulted in 32% reduced protein secre-
tion (ATDC5 d4).
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FUNCTION OF THE CHONDROCYTE PI-3 KINASE-AKT SIGNALING
PATHWAY IS STIMULUS DEPENDENT
M.A. Greene y,z, R.F. Loeser z. yWake Forest Univ. Sch. of Med., Winston-
Salem, NC, USA; z The Univ. of North Carolina at Chapel Hill, Chapel Hill,
NC, USA
Purpose: The PI-3 kinase-Akt pathway plays a role in cartilage
anabolic and catabolic processes in response to activation by insulin-
like growth factor-1 (IGF-1) and the pro-inﬂammatory cytokines
interleukin-1b (IL-1b) and oncostatin M (OSM). IGF-1 promotes
proteoglycan and collagen II synthesis while IL-1b and OSM promoteincreased MMP production and matrix degradation. These stimuli
share activation of the PI-3 kinase-Akt pathway, which has led some
groups to suggest that inhibition of this pathway would be an
effective therapeutic target in the treatment of OA. The goal of this
study was to determine how PI-3 kinase-Akt signaling regulates
these seemingly opposing functions.
Methods: Human articular chondrocytes were isolated from normal
human ankle (talar) and knee cartilage. Primary conﬂuent monolayer
cultures were serum-starved overnight before treatment with IGF-1
(100ng/mL), IL-1b (10ng/mL), OSM (10ng/mL), or IL-1bþOSM (10ng/
mLþ10ng/mL). In experiments with chemical inhibitors, cells were pre-
treated with the inhibitor or DMSO vehicle for 30min before treatment
with IGF-1, IL-1b, OSM, or IL-1bþOSM. Activation of signaling proteins
was measured by immunoblotting of the total cell lysate with phospho-
speciﬁc antibodies. MMP-13 production was measured by immuno-
blotting of the conditioned media and ELISA. Constitutively active Akt1
and Akt3 were expressed by lentiviral transduction and plasmid
nucleofection, respectively, to study stimulus-independent activation of
Akt.
Results: In time course experiments (0-60min), IGF-1, OSM, and the
combination of IL-1b and OSM but not IL-1b alone, stimulated
phosphorylation of Akt which was sustained longer with IGF-1 (Fig
1). IL-1bþOSM, but not IGF-1, increased chondrocyte MMP-13 pro-
duction which was inhibited with either a general PI-3 kinase
inhibitor (p¼0.0176) or speciﬁc inhibition of the PI-3 kinase-g iso-
form (p¼0.0358). Over-expression of constitutively active Akt1 or
Akt3 was not sufﬁcient to increase production of MMP-13 either in
un-stimulated cells or cells treated with the combination of IL-1b
and OSM. Inhibition of the ERK, JNK, and p38 MAP kinase pathways
as well as the JAK/STAT pathway signiﬁcantly inhibited the IL-
1bþOSM mediated MMP-13 production (densitometric analysis from
3 independent donors: p<0.0001 for all inhibitors, Fig 2). The JNK,
p38, and JAK/STAT pathways were activated by IL-1bþOSM but not
by IGF-1 (Fig 1). Additionally, inhibition of the JAK/STAT pathway
blocked IL-1b/OSM mediated p-Akt but had no effect on IGF-1
mediated p-Akt.
Conclusions: The chondrocyte integrates signals from the PI-3 kinase-
Akt pathway with signals from MAP kinases and the JAK-STAT pathway
to allow for a differential response to a pro-anabolic (IGF-1) and a pro-
catabolic (IL-1bþOSM) stimulus. Due to the ability of the JAK/STAT
inhibitor to block IL-1bþOSM mediated p-Akt and MMP-13 without
blocking IGF-1 mediated p-Akt, we suggest the JAK/STAT pathway as a
more effective therapeutic target in the treatment of OA than the PI-3
kinase-Akt pathway.Figure 1. Primary human chondrocytes were treated with IGF-1, IL-1b,
OSM, or IL-1b/OSM over a time course from 0-60min. Total cell lysates
were immunoblotted with phospho-speciﬁc antibodies. Total protein
blots are shown as loading controls.
